Jump to content

PubMed RSS Feed - -Tranexamic acid microinjections : a novel treatment option for erythematotelangiectatic rosacea


Recommended Posts

J Cosmet Dermatol. 2021 May 10. doi: 10.1111/jocd.14209. Online ahead of print.


BACKGROUND: Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.

AIMS: to evaluate the efficacy and safety of intradermal microinjections of TXA for ETR.

PATIENTS/METHODS: This was a retrospective study enrolling patients, treated with TXA intradermal microinjections for ETR, from January 2019 to February 2020. Response to treatment was assessed based on subjective symptoms, clinical photographs and the Investigator Global Assessment of Rosacea Severity Score (IGA-RSS).

RESULTS: Six patients were included. The mean number of monthly intradermal TXA microinjections was 5.1±1.3. The mean decrease of IGA-RSS was 2.4±0.5. Local side effects, mainly transient erythema and swelling, were noticed in three cases. No systemic effects were noted. Clinical improvement, in respondent patients, lasted after 3 months of follow-up.

CONCLUSION: Intradermal TXA microinjections is a safe and effective treatment option for ETR. The optimal number of monthly sessions has yet to be determined.

PMID:33973361 | DOI:10.1111/jocd.14209

{url} = URL to article

More information on TXA 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...